Bruker (BRKR) vs Revvity (RVTY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bruker (BRKR) has outperformed Revvity (RVTY) over the past year, gaining 67.3% versus a gain of 65.8%. Over five years, RVTY leads with a -10.4% price change compared with -22.7% for BRKR. Revvity is the larger company by market cap ($16.98 billion vs $8.82 billion), about 1.9 times the size.
On valuation, Bruker trades at a lower forward P/E (24.0x vs 25.8x for Revvity). Bruker offers the higher dividend yield (0.35% vs 0.18%). Revvity converts more of its revenue into profit, with a net margin of 8.4% versus -0.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRKR | RVTY |
|---|---|---|
| Share price | $57.92 | $152.16 |
| Market cap | $8.82B | $16.98B |
| 1-day change | -3.01% | -0.94% |
| YTD return | +22.95% | +57.27% |
| 1-year return | +67.25% | +65.81% |
| 5-year return | -22.67% | -10.40% |
| P/E ratio (TTM) | — | 72.80 |
| Forward P/E | 24.01 | 25.82 |
| EPS (TTM) | $-0.70 | $2.09 |
| Dividend yield | 0.35% | 0.18% |
| Annual dividend | $0.20 | $0.28 |
| Revenue (latest FY) | $3.44B | $2.86B |
| Revenue growth (YoY) | +2.08% | +3.67% |
| Net income (latest FY) | $-8.60M | $241.20M |
| Gross margin | 45.91% | — |
| Operating margin | 1.98% | 12.49% |
| Net margin | -0.25% | 8.45% |
| 52-week high | $66.98 | $166.25 |
| 52-week low | $32.37 | $81.22 |
| Distance from 52-week high | -13.53% | -8.48% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +9.20% | -10.71% |
| Average volume | 2.24M | 1.79M |
| Shares outstanding | 152.36M | 111.59M |
| Employees | 11,085 | 11,000 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Revvity is more profitable, keeping 8.4 cents of every revenue dollar as net income versus -0.3 cents for Bruker.
About Bruker
BRKR stock →Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,085 employees
About Revvity
RVTY stock →Revvity, Inc. provides health sciences solutions, technologies, and services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,000 employees
BRKR vs RVTY FAQ
Which is bigger, Bruker or Revvity?
Revvity (RVTY) is larger, with a market capitalization of $16.98B compared with $8.82B for Bruker (BRKR).
Which stock has performed better over the past year, BRKR or RVTY?
BRKR returned +67.25% over the past 12 months, compared with +65.81% for RVTY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Bruker or Revvity?
Bruker has the higher yield at 0.35%, compared with 0.18% for Revvity.
Are Bruker and Revvity in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.